AHNAK2 and gastric cancer: This may explain why AHNAK2 is associated with the progression of patients with unresectable metastatic gastric cancer and could provide an explanation for an AHNAK2-mRNA expressions link to worsening survival in PDAC, as advanced metastatic PDAC is now treated with FOLFIRNOX (Folinic acid, 5-FU, irinotecan and oxaliplatin).